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MYOCARDIAL REVASCULARIZATION AFTER ACUTE 
MYOCARDIAL INFARCTION 
● Myocardial revascularization procedures represent important treatment options for 
patients with acute and chronic coronary artery disease (CAD). 
● Acute myocardial infarction (MI) was identified nearly 50 years ago as a coronary 
occlusive event resulting from atherosclerotic plaque rupture and thrombosis. This 
mechanistic understanding was essential to the development of reperfusion 
therapy for treating ST-segment elevation MI (STEMI). 
● The treatment of STEMI has advanced since the introduction of reperfusion 
therapies. 
● Mechanical reperfusion with primary percutaneous coronary intervention is now the 
standard of care.  
 
 
 
 
 
 
 
 
 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880555/ 
 
IN-STENT RESTENOSIS 
● The introduction of bare metal stents (BMS) was a significant milestone in the 
evolution of percutaneous coronary intervention. Soon after it was apparent that 
these stents led to in-stent restenosis (ISR), which requires repeat 
revascularization. 
● Restenosis is defined as a reduction in lumen diameter after percutaneous 
coronary intervention (PCI), either with or without stent implantation.  
● In-stent restenosis currently defined as a >50% stenosis of a previously stented 
segment, occurs in 30% of all patients receiving BMS. 
  
 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107494/ 
 
BALLOON ANGIOPLASTY FOR THE TREATMENT OF 
CORONARY IN-STENT RESTENOSIS 
 
Balloon angioplasty (BA) was one of the earliest strategies used in patients 
experiencing ISR. The procedure is technically straightforward and consistently 
associated with satisfactory acute results and a very low incidence of complications. 
Currently available therapeutic modalities, such as drug-coated balloons (DCB) and 
drug-eluting stents (DES) provide the best clinical and angiographic results in 
patients with ISR. However, the field is rapidly evolving. Further studies are required 
to identify clinical and anatomic characteristics that may help to refine selection and 
tailor available therapeutic strategies to improve clinical outcomes. 
 
 
 
 
 
 
 
 
https://www.sciencedirect.com/science/article/pii/S0735109714013540 
 
OUR PATIENT PROFILE  
•51 years old (01.06.1968) 
•Male 
•Retired 
•Lives in a village 
•Hospitalized  on 18.10.18 to the cardiological 
department of City Clinical Hospital № 8 
COMPLAINTS  
Main 
• Disruptions of the heart beats and heart palpitations which are related 
to physical activity  
• Shortness of breath when walking (observed during physical exertion, 
while ascending the staircase to the fifth floor), disappearing after the 
rest 
• Unstable blood pressure (increasing of BP in the range of 160/90 
mmHg – 180/100 mmHg, despite taking hypotensive drugs, – 
Bicoprolol, Ramipril) 
Additional: 
Fatigue 
General weakness 
 
MEDICAL HISTORY  1.2 
● Hypertension for 10 years with the maximum blood pressure (BP) 
over 180/100 mm Hg 
● The usual BP is about 140/90 mm ​​Hg (antihypertensive drugs – 
Bisoprolol 5 mg, Ramipril 5 mg  
● Since 2009, the blood pressure measured noted to be consistently 
elevated in the range of 160/100 mmHg – 180/100 mmHg on three 
occasions 
● On August  18 2016 was diagnosed with Non-Q-wave myocardial 
infarction (left ventricular posterior wall myocardial infarction) 
● On September 7  2016 was performed coronary angiography and 
heart catheterization 
 
 
MEDICAL HISTORY  2.2 
● On September 18  2016 was performed coronary angiography with implantation 
of two non–drug-eluting stents 
● On February 2017 symptoms of progressive unstable angina, diagnosed in-stent 
restenosis, completed balloon angioplasty 
● On October 2018 admitted to the cardiological department with complaints: 
palpitations that were connected with physical exercises; breathlessness while 
ascending to the fifth floor 
● Hospitalized with the diagnoses: Ischemic Heart Disease. Postinfarction 
(posterior STEMI of LV 18.08.16) cardiosclerosis. Arterial Hypertension, stage III, 
grade 2, high risk. Chronic heart failure, NYHA class II, stage С, with preserved 
EF (50%). Patient hospitalized to the cardiological department of CCH №8 for 
examination and correction of the treatment. 
MEDICAL HISTORY - CORONARY ANGIOGRAPHY  
A - Angiography showed the left anterior 
descending coronary artery stenosis (50%) 
B - the left circumflex artery occlusion of the 
distal segment 
C - occlusion of the obtuse marginal branch 
A 
B C 
7.08.16 27.09.16 
D - During angiography performed 
recanalization of occlusion of the distal 
segment with Ryujin balloon 1.5 cm * 15 
mm with implantation of two Bare – Metal 
Stents: Chroma 2.25 * 14 mm and  
Chroma 2.75 * 24 mm.  
D 
MEDICAL HISTORY - BALLOON 
ANGIOPLASTY (17.02.17)  
 
● Patient admitted to the cardiological department with symptoms of 
progressive unstable angina. 
● The Coronary Angiography revealed restenosis of a stented 
segment to the level of subocclusion, with chronic occlusion of the 
obtuse marginal branch. The right coronary artery was without 
significant hemodynamic disturbances.  
● During angiography performed angioplasty of the restenosis with NC 
Sprinter ballon 2.5 * 15 mm.  
HISTORY OF LIFE  
• Was born in a full family, developed according to age 
• Denies tuberculosis, diabetes, malaria, viral hepatitis, sexually 
transmitted diseases and AIDS 
• Denies allergic reactions to drugs  
• Non-smoker 
• Denies alcohol consumption 
• Sedentary lifestyle  
• Hasn’t checked his lipid  and glucose profile over 6 months 
• Hereditary - no family history of cardiovascular disease 
OBJECTIVE STATE: 1.2 
• The general condition is satisfactory, consciousness is clear, 
emotionally stable, optimistic mood 
• Hypersthenic, height 176 cm, weight 80 kg, BMI = 25.8 kg / 
m2, waist-to-hip ratio 0,90 
• Skin, visible mucous membranes are pale pink and clean 
• Peripheral lymph nodes are not palpable 
• The thyroid is not palpable 
 
 
OBJECTIVE STATE: 2.2  
• Respiratory System: Pulmonary percussion – resonant sound, 
auscultation - vesicular breathing , no adventitious sounds 
• Cardiovascular system: Heart borders extended to the left on 1,5 cm 
of midclavicular line,  HR =76 bpm, regular. Ps= 76 bpm. No pulse 
deficiency 
• Heart sounds are muted, accent of the II tone above the aorta.  
• BP dextr = BPsin= 140/80 mm Hg (on the background of 
antihypertensive therapy) 
• Gastrointestinal system: Abdomen is soft, painless, symmetrical, no 
discrepancies of the abdominal muscles.  
• No visible peristalsis.  
• Liver edge is smooth, painless , palpated 2 cm below the costal  arch. 
• Spleen and pancreas are not palpable 
• No pitting oedema 
 
EXAMINATION 
 Examination, completed  in the 
hospital 
• General blood test 
• General urine test 
• Biochemical blood test (Liver and 
renal function tests) 
• Blood lipid spectrum 
• Blood glucose level  
• Electrocardiography 
• Echocardiography 
• 24 hours electrocardiography 
monitoring 
• Stress test ( Cycle Ergometer test) 
Recommended additional 
examination 
• Blood glucose level (Hb A1c) 
• Random glucose test 
• Blood electrolytes (K, Na) 
• Cardiologist consultation 
• Endocrinologist consultation 
Ultrasonography of the abdomen (liver, 
gallbladder, pancreas, kidneys) 
This tests wasn’t completed  for 
financial reasons.  
 
COMPLETE BLOOD TEST (19.10.18)  
MEASURE RESULT  RATE  
Hemoglobin 154 M 130 - 160 g / l  
Erythrocytes 5.04  M 4.0-5.0 T / l 
Color index 1.06  0,85 – 1,15 
Leukocytes 6.9 4,0 – 9,0 g/L 
ESR 11 M 2-12 mm/h 
Platelets  260 160-320 g/L 
Band Neutrophils 1  1-6 % 
Segmented Neutrophils 52 47-72 % 
Eosinophils  1  0,5-5,0%  
Basophils 0 1-1,0 % 
Monocytes  3 3-11 % 
Lymphocytes 43 19-37% 
Conclusion: erythrocytosis   
http://www.endmemo.com/medical/unitconvert/Dimethadione.php 
 
GENERAL URINE TEST (19.10.18) 
MEASURE  RESULT NORMAL RANGE  
SPECIFIC GRAVITY 1.012  1,001-1,040 
REACTION 6,8  5,0-7,0 
PROTEIN  0.020 to 0.033 g / l  
GLUCOSE 0 Absent  
LEUCOCYTES 1-2 6-8  
EPITHELIUM TRANSITION Not detected  Not detected  
BACTERIA Not detected  Not detected  
Conclusion: normal  
http://www.endmemo.com/medical/unitconvert/Dimethadione.php 
BIOCHEMICAL BLOOD TEST (19.10.18) 
MEASURE  RESULT NORMAL RANGE  
AsAt  27,8 <37 u/L 
AlAt  60  <41 u/L 
Fasting glucose 6,2 4,2-6,1 mmol/l 
Creatinine 91,5 80-115 mcmol/L 
Conclusion:  elevated transaminases, hyperglycemia.  
  
http://www.endmemo.com/medical/unitconvert/Dimethadione.php 
 
GLOMERULAR FILTRATION 
RATE 
 
RESULT NORMAL RANGE 
GFR (Cockroft - Gault) 85.4  >90 ml/min/1.73m2 
GFR (CKD-EPI) 83.2  >90 ml/min/1.73m2 
GFR (MDRD) 81  >90 ml/min/1.73m2 
Conclusion:   According to GFR level, mildly reduced kidney function. 
BLOOD LIPID SPECTRUM (19.10.18) 
MEASURE RESULT  RATE  
Total Cholesterol 3,7  ≤ 5,2 mmol / l (<4,5) 
VLDL 0,97 <1,0 mmol / l  
LDL 1,92 <3,5 mmol / l  
HDL- cholesterol levels 0,81  >0,9 mmol / l  
Triglycerides  2,13  ≤2,3 mmol / l  
Coefficient of atherogenicity  3,57 to 3,0 mmol/l  
Conclusion: increased coefficient of atherogenicity due to the level of HDL 
http://eurheartj.oxfordjournals.org/content/ehj/34/39/3035.full.pdf 
ECG (18.10.18) 
Result:  sinus 
rhythm, normal heart 
axis,  with heart rate 
54 bpm. Posterior 
wall repolarization 
interruption.  
 
 
 
 
 
 
24 HOURS ELECTROCARDIOGRAPHY MONITORING 
(18.10.18) 
Result: during 24-hours 
monitoring registered sinus 
rhythm,  supraventricular 
premature contractions (total 
210); short supraventricular 
tachycardia episodes; 
monomorphic ventricular 
premature contractions (total 
10). Daily heart rate - 55 
beats/min (bpm), night heart rate 
- 55 beats/min (bpm).  
Principles of diagnostic testing 
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Stable-Coronary-Artery-Disease-Management-of 
CYCLE ERGOMETER STRESS TESTING FOR IDENTIFICATION 
OF SIGNIFICANT CORONARY ARTERY DISEASE (19.10.18) 
• The bicycle ergometer test was carried out according to the 
incremental workloads calibrated in watts (W). The protocol 
started with a power output of 10W/minutes, followed by 
increases of 25 W/min. every 3 min.  
• The test was negative.  Stopped after reaching the 150 
W/min, the appearance of chest pain, heavy chest 
pressure, difficulty in breathing. The duration of the last step 
– 1 min. 30 sec.  
• After stopping the test ECG showed ST segment without 
specific changes, registered infrequent ventricular 
extrasystoles without signs of coronary insufficiency, blood 
pressure - 210/100 mmHg, heart rate - 110 beats/min 
(bpm). 
• Period of restitution was without specific features. Blood 
pressure recovered in 5 min. to 120/80 mmHg, chest pain 
relieved in 2 min. 
 
ECHOCARDIOGRAPHY:1.2 (23.10.18) 
Name Result Normal 
1) Aorta  37 mm.  20-37 mm 
2) Aortic Valve   Opening 18 mm 17-26 mm 
3) Left Atrium Antero-posterior size: 50 mm To  38 mm 
4) Mitral Valve No regurgitation 
5) Posterior wall of 
the LV  
11 mm. Contraction – normokinetic.  6-11 mm 
6) LV end-diastolic 
diameter 
58 mm 46-57 mm 
7) LV end-systolic 
diameter 
43 mm 31 - 43 mm 
https://www.asecho.org/wp-content/uploads/2015/01/ChamberQuantification2015.pdf 
ECHOCARDIOGRAPHY:2.2 
Name Result Normal 
8) Interventricular septum 11 mm 6-11 mm 
 
9) Right Ventricle D.: 24 mm D.: (9-26 mm). Thickness of the 
wall 3-6 mm 
10) Right Atrium 38 mm <44 mm 
11) Tricuspid Valve No regurgitation 
10)Ejection Fraction 50% 55-78% 
Conclusion: sclerotic changes of aortic walls, aortic valve. 
Dilation of the left ventricle and atrium. Left ventricular 
hypertrophy.  
https://www.asecho.org/wp-content/uploads/2015/01/ChamberQuantification2015.pdf 
 
BASIC CLINICAL SYNDROMES 
• Atherosclerosis (sclerotic changes of aortic valve, 
mild atherosclerotic aortic stenosis)* 
• Arterial hypertension * 
• Arrhythmias (permanent (constant) AF) 
• Heart failure 
• Dyslipidemia* 
• Hypertensive  heart (LVH, atrial enlargement, 
increased diastolic stiffness)* 
• Hepatomegaly, liver steatosis 
• Erythrocytosis, hemoconcentration  
• Hyperglycemia / glycosuria syndrome* 
• Obesity: BMI = 25.8 kg / m2, waist-to-hip ratio 0,90* 
• * - features of metabolic syndrome 
 
The clinical diagnosis 
according to current 
classifications 
Weight 
categories 
BMI 
(kg/m2) 
Underweight <18.5 
Healthy 
weight 
18.5-24.9 
Overweight 25-29.9 
Obese 30-34.9 
Severely 
Obese 
35-39.9 
Morbidly 
Obese 
>40 
CATEGORIES WAIST-TO-HIP RATIO 
Health risk Men 
Low 0.80 or lower 
Moderate 0.81-0.85 
High >0.86 
CLASSIFICATION OF OVERWEIGHT AND 
OBESITY AND WAIST-TO-HIP RATIO 
 
http://www.bmi-calculator.net/waist-to-hip-ratio-calculator/ 
 
DEFINITIONS AND CLASSIFICATION OF OFFICE 
BLOOD PRESSURE LEVELS (MMHG) 
 Category Systolic Diastolic 
Optimal <120 and <80 
Normal 120-129 and/o
r 
80-84 
High normal 130-139 and/o
r 
85-89 
Grade 1 
hypertension 
140-159 and/o
r 
90-99 
Grade 2 
hypertension 
160-179 and/o
r 
100-109 
Grade 3 
hypertension 
≥180 and/o
r 
≥110 
Isolated 
systolic 
hypertension 
≥140 and <90 
http://www.esh2013.org/wordpress/wp-content/uploads/2013/06/ESC-ESH-Guidelines-2013.pdf 
Stage The degree of target organ damage 
I Objective changes in the target organs are absent 
II There is objective evidence of target organ damage without symptoms with their hand or dysfunction: 
 Left ventricular hypertrophy (on ECG, ultrasound, Ro) 
 Generalized narrowing of retinal arteries 
 Microalbuminuria and / or a small increase in serum creatinine (y m. - 115 - 133 mmol / L at x. - 107 - 124 mmol / l)  
Carotid artery disease - a thickening of the intima-media> 0.9 mm or the presence of atherosclerotic plaques 
III There is objective evidence of target organ damage with symptoms from their side and impaired heart - myocardial 
infarction, heart failure II A - III stage;  brain - stroke, transient ischemic attack, acute hypertensive encephalopathy, vascular 
dementia; fundus - hemorrhage and retinal exudates with papilledema the optic nerve or without;  kidney - concentration of plasma 
creatinine in males> 133 umol / L, y Women> 124; vessels - dissecting aortic aneurysm; peripheral arterial occlusion 
Functional capacity Objective Assessment 
Class I - No symptoms and no limitation in ordinary physical 
activity, e.g. shortness of breath when walking, climbing stairs etc. 
 
Class A. No objective evidence of cardiovascular disease.  
Class II - Mild symptoms (mild shortness of breath and/or 
angina) and slight limitation during ordinary activity. 
 
Class B. Objective evidence of minimal cardiovascular disease.  
Class III - Marked limitation in activity due to symptoms, even 
during less-than-ordinary activity, e.g. walking short distances 
(20—100 m).Comfortable only at rest. 
 
Class C. Objective evidence of moderately severe cardiovascular 
disease.  
Class IV - Severe limitations. Experiences symptoms even while at 
rest. Mostly bedbound patients. 
 
Class D. Objective evidence of severe cardiovascular disease.  
THE NEW YORK HEART ASSOCIATION 
(NYHA) FUNCTIONAL CLASSIFICATION 
(FUNCTIONAL CAPACITY) OF CHF 
AMERICAN HEART ASSOCIATION  
HEART FAILURE STAGES 
COMPLETE DIAGNOSIS OF OUR PATIENT: 
OUR CLINICAL DIAGNOSIS 
Main:  
ISCHAEMIC HEART DISEASE. POSTINFARCTION 
(POSTERIAL STEMI OF LV 18.08.16) 
CARDIOSCLEROSIS. 
7.08.16 CORONARY ANGIOGRAPHY, 27.09.16 
CORONARY ARTERY STENTING WITH TWO 
BARE-METAL STENTS, 17.02.17 BALLOON 
ANGIOPLASTY AFTER STENT RESTENOSIS. 
SYSTEMIC ATHEROSCLEROSIS 
(ATHEROSCLEROSIS OF THE AORTA) 
ESSENTIAL ARTERIAL HYPERTENSION STAGE 
III, 2 GRADE. HYPERTENSIVE HEART (LVH) 
CHRONIC HEART FAILURE WITH PRESERVED 
LEFT VENTRICLE EJECTION FRACTION ( EF- 
50%),  II CLASS,  STAGE C NYHA. 
VERY HIGH ADDED TOTAL CV RISK 
Co-morbidity:  Pre- diabetes? 
 
 
 
HEALTH FACILITY DIAGNOSIS 
Main:  
ISCHAEMIC HEART DISEASE. ANGINA 
PECTORIS CLASS III.  
POSTINFARCTION (POSTERIAL STEMI OF LV 
18.08.16) CARDIOSCLEROSIS. 
SYSTEMIC ATHEROSCLEROSIS 
(ATHEROSCLEROSIS OF THE AORTA) 
ARTERIAL HYPERTENSION STAGE III, 3 
GRADE 
HYPERTENSIVE HEART (LVH) 
 
 
TREATMENT 
•Lifestyle modification  
•Medical intervention 
THERAPEUTIC LIFESTYLE CHANGES 
PARAMETER TREATMENT GOAL 
 Weight loss 
(for overweight and obese patients) 
Reduce by 5% to 10%  
 Physical activity 
• At least 150 minutes of moderate-intensity physical activity 
(for example, 30 minutes, 5 days a week), 
or 
• At least 75 minutes of vigorous-intensity physical activity (for 
example, 25 minutes, 3 days a week); or 
• A combination of moderate- and vigorous-intensity aerobic 
activity, and 
• At least 2 days of moderate- to high-intensity muscle-
strengthening activities (such as resistance 
weight training) for additional health benefits 
 Diet 
• Vegetables, fruits, and whole grains 
• Legumes and nuts 
• Low-fat dairy products 
• Low-fat poultry (without the skin) 
• Fish and seafood 
• Nontropical vegetable oils 
https://www.heart.org/-/media/files/health-topics/cholesterol/chlstrmngmntgd_181110.pdf 
TREATMENT STRATEGY 1.2. 
 
Our goals: 
 
• BP target – 130-139/85-89 mm Hg 
• n LDL-C target of 1.8 mmol/L (70 mg/dL)  
• Glycated Hemoglobin (HbA1c) to ,7.0% (53 mmol/mol) 
 
 
 
 
 
 
 
  
According to the ESC Clinical Practice Guidelines 2013, Management of Stable Coronary Artery Disease  
 
 
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Stable-Coronary-Artery-Disease-Management-of 
HEALTH FACILITY 
TREATMENT 
 
Drug therapy 
• Bisoprolol 5 mg in the morning 
• Enalapril 5 mg in the morning 
• Aspirin 100 mg in the evening 
• Clopidogrel 75 mg in the evening 
• Atorvastatin 40 mg in the evening 
IV therapy 
•Meldonium 500mg / 5.0 ml, N10  
RECOMMENDED 
TREATMENT 
 
Drug therapy 
•Angiotensin-converting enzyme (ACE) 
inhibitor-Ramipril 5 mg in the morning 
•Diuretic – Eplerenone 25 mg, in the 
morning 
•Β- blocker-Bisoprolol 5 mg in the morning 
(target HR – 60 b/m) 
•Antiplatelet therapy - Aspirin 100 mg in the 
evening 
•Antiplatelet agent - Clopidogrel 75 mg in 
the evening 
•Statin- Rosuvastatin  20 mg in the evening 
CONTROL OF COMPLIANCE 
TO MEDICAL 
RECOMMENDATIONS (diet, 
weight, physical activity, 
drug treatment) ! 
RECOMMENDATIONS FOR 
FURTHER EXAMINATION 
• Exercise ECG 
• 24h-ECG monitoring 
• Daily glycemic profile, Glucose tolerance test, 
HbA1C, consultation of Endocrinologist 
• Echocardiography for evaluation of diastolic 
function of LV 
• Lipid profile (LDL), ALT (liver)  
 
 
 
 
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines 
 
PROGNOSIS 
•Prognosis for life - non-compliance to 
doctor's appointments – non-
satisfactory  
•The prognosis for recovery -  
unfavorable 
Conclusions  
 
● In our clinical case, according to the result of cardiac stress test, when 
veloergometer cycle test showed no signs of myocardial ischemia, balloon 
angioplasty has proven to be an effective method of In-stent restenosis 
treatment.  
● Considering that Diabetes mellitus has a role in foster the In-stent restenosis 
process, further diagnostic recommended: HbA1c, fasting plasma glucose 
and postprandial glucose level control, glucose tolerance test. 
● To clarify the segmental heart contractility, we recommend additionally a 
Stress-echo test and Speckle tracking echocardiography.  
● Repeat Coronarography in case of cardiac ischemia signs. 
 
 
 
 
THANK YOU FOR 
ATTENTION! 
